Drug Discovery for Parasitic Diseases

 描述（由申请人提供）：要求对Leann M.蒂利，菲利普J罗森塔尔和凯利Chibale。会议将于2016年1月24日至28日在加州的太浩城举行。包括原生动物和蠕虫在内的寄生生物是最重要的人类病原体之一，每年造成数十亿人感染和数百万人死亡。对于许多寄生虫病，现有的治疗方法不能令人满意，并且日益受到耐药性的威胁。迫切需要新的治疗方法，理想地针对新的靶点。抗寄生虫药物发现的最新进展来自三种不同的方法-基于寄生虫生物学的靶向方法;受益于改进的技术的表型高通量筛选;以及重新定位和重新利用为其他适应症开发的药物。这些不同的方法都受益于药物化学与寄生虫学和药物治疗计划的整合。本次会议将展示尖端的抗寄生虫药物发现计划，说明从寄生虫生物学到领导识别和从优化到候选人选择的路径。它将强调药物化学，寄生虫生物学，药代动力学和安全性评估程序的协调整合的必要性。它将以促进药物发现的化学生物学、化学蛋白质组学、化学信息学、基因组学、转录组学和代谢组学等新兴技术为特色。它还将讨论抗寄生虫药物耐药性的现状和我们对耐药机制的理解进展。这次会议应该引起药物化学家、寄生虫学家、药物发现和开发专家、药理学家和临床医生的兴趣，这些专家的目标是引起严重人类疾病的原生动物和蠕虫，包括疟疾、非洲和美洲锥虫病、利什曼病、血吸虫病和多种其他寄生虫感染。

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Drug Discovery for Parasitic Diseases, organized by Leann M. Tilley, Philip J. Rosenthal and Kelly Chibale. The meeting will be held in Tahoe City, California from January 24-28, 2016. Parasitic organisms, including protozoa and helminths, are among the most significant human pathogens, causing billions of infections and millions of deaths each year. For many parasitic diseases, available therapies are unsatisfactory and increasingly threatened by drug resistance. New therapies, ideally directed against novel targets, are urgently needed. Recent advances in anti-parasitic drug discovery have come from three different approaches - target-based methods that build on improved understanding of parasite biology; phenotypic high throughput screens, that are benefitting from improved technology; and repositioning and repurposing drugs developed for other indications. These different approaches all benefit from the integration of medicinal chemistry with parasitology and pharmacotherapy programs. This conference will showcase cutting-edge anti-parasitic drug discovery programs that illustrate the path from parasite biology to lead identification and from optimization to candidate selection. It will emphasize the need for coordinated integration of programs in medicinal chemistry, parasite biology, pharmacokinetics, and safety assessment. It will feature emerging technologies such as chemical biology, chemoproteomics, chemical informatics, genomics, transcriptomics and metabolomics that are facilitating drug discovery. It will also discuss the current status of anti-parasitic drug resistance and advances in our understanding of mechanisms of resistance. The conference should be of interest to medicinal chemists, parasitologists, experts in drug discovery and development, pharmacologists and clinicians targeting the protozoa and helminths that cause serious human disease, including malaria, African and American trypanosomiasis, leishmaniasis, schistosomiasis and multiple other parasitic infections.